Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Ciprofloxacin Viatris

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Ciprofloxacin Testmiljö

Ciprofloxacin

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Rocha JL, Tuon FF, Johnson JR. Sex, drugs, bugs, and age: rational selection of empirical therapy for outpatient urinary tract infection in an era of extensive antimicrobial resistance. Braz J Infect Dis. 2012;16:115-21.

  2. van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care. 2008;23:422-30.

  3. Overholser BR, Kays MB, Forrest A, Sowinski KM. Sex-related differences in the pharmacokinetics of oral ciprofloxacin. J Clin Pharmacol. 2004;44:1012-22.

  4. Konieczna L, Chmielewska A, Lamparczyk H. Influence of sex on the pharmacokinetics of ciprofloxacin and ofloxacin. Chemotherapy. 2006;52:111-21.

  5. Höffler D, Dalhoff A, Gau W, Beermann D, Michl A. Dose- and sex-independent disposition of ciprofloxacin. Eur J Clin Microbiol. 1984;3:363-6.

  6. Gallicano K, Sahai J. Lack of gender effect on ciprofloxacin pharmacokinetics in humans. Br J Clin Pharmacol. 1996;42:632-4.

  7. Shah A, Lettieri J, Nix D, Wilton J, Heller AH. Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects. Antimicrob Agents Chemother. 1995;39:1003-6.

  8. Ciproxin (ciprofloxacin). Summary of Product Characteristics. Swedish Medical Products Agency (MPA) [updated 2022-02-01, cited 2022-06-16]

  9. Gunderson BW, Ross GH, Ibrahim KH, Rotschafer JC. What do we really know about antibiotic pharmacodynamics?. Pharmacotherapy. 2001;21:302S-318S.

  10. den Heijer CD, Donker GA, Maes J, Stobberingh EE. Antibiotic susceptibility of unselected uropathogenic Escherichia coli from female Dutch general practice patients: a comparison of two surveys with a 5 year interval. J Antimicrob Chemother. 2010;65:2128-33.

  11. den Heijer CD, Penders J, Donker GA, Bruggeman CA, Stobberingh EE. The importance of gender-stratified antibiotic resistance surveillance of unselected uropathogens: a Dutch Nationwide Extramural Surveillance study. PLoS One. 2013;8:e60497.

  12. McGregor JC, Elman MR, Bearden DT, Smith DH. Sex- and age-specific trends in antibiotic resistance patterns of Escherichia coli urinary isolates from outpatients. BMC Fam Pract. 2013;14:25.

  13. Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009). BMC Infect Dis. 2013;13:19.

  14. Mostafavi SN, Rostami S, Rezaee Nejad Y, Ataei B, Mobasherizadeh S, Cheraghi A et al. Antimicrobial Resistance in Hospitalized Patients with Community Acquired Urinary Tract Infection in Isfahan, Iran. Arch Iran Med. 2021;24(3):187-192.

  15. Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology. 2011;120(2):103-10.

  16. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.

  17. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.]

  1. Rocha JL, Tuon FF, Johnson JR. Sex, drugs, bugs, and age: rational selection of empirical therapy for outpatient urinary tract infection in an era of extensive antimicrobial resistance. Braz J Infect Dis. 2012;16:115-21.
  2. van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care. 2008;23:422-30.
  3. Overholser BR, Kays MB, Forrest A, Sowinski KM. Sex-related differences in the pharmacokinetics of oral ciprofloxacin. J Clin Pharmacol. 2004;44:1012-22.
  4. Konieczna L, Chmielewska A, Lamparczyk H. Influence of sex on the pharmacokinetics of ciprofloxacin and ofloxacin. Chemotherapy. 2006;52:111-21.
  5. Höffler D, Dalhoff A, Gau W, Beermann D, Michl A. Dose- and sex-independent disposition of ciprofloxacin. Eur J Clin Microbiol. 1984;3:363-6.
  6. Gallicano K, Sahai J. Lack of gender effect on ciprofloxacin pharmacokinetics in humans. Br J Clin Pharmacol. 1996;42:632-4.
  7. Shah A, Lettieri J, Nix D, Wilton J, Heller AH. Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects. Antimicrob Agents Chemother. 1995;39:1003-6.
  8. Ciproxin (ciprofloxacin). Summary of Product Characteristics. Swedish Medical Products Agency (MPA) [updated 2022-02-01, cited 2022-06-16]
  9. Gunderson BW, Ross GH, Ibrahim KH, Rotschafer JC. What do we really know about antibiotic pharmacodynamics?. Pharmacotherapy. 2001;21:302S-318S.
  10. den Heijer CD, Donker GA, Maes J, Stobberingh EE. Antibiotic susceptibility of unselected uropathogenic Escherichia coli from female Dutch general practice patients: a comparison of two surveys with a 5 year interval. J Antimicrob Chemother. 2010;65:2128-33.
  11. den Heijer CD, Penders J, Donker GA, Bruggeman CA, Stobberingh EE. The importance of gender-stratified antibiotic resistance surveillance of unselected uropathogens: a Dutch Nationwide Extramural Surveillance study. PLoS One. 2013;8:e60497.
  12. McGregor JC, Elman MR, Bearden DT, Smith DH. Sex- and age-specific trends in antibiotic resistance patterns of Escherichia coli urinary isolates from outpatients. BMC Fam Pract. 2013;14:25.
  13. Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009). BMC Infect Dis. 2013;13:19.
  14. Mostafavi SN, Rostami S, Rezaee Nejad Y, Ataei B, Mobasherizadeh S, Cheraghi A et al. Antimicrobial Resistance in Hospitalized Patients with Community Acquired Urinary Tract Infection in Isfahan, Iran. Arch Iran Med. 2021;24(3):187-192.
  15. Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology. 2011;120(2):103-10.
  16. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.
  17. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.]